Friday, April 14, 2023 4:39:27 AM
On the other hand there are people affiliated with Mymetics which certainly know how to make money. And they will do their best to maximize the outcome, naturally for themselves firstly in the sense of getting back the company owes them and secondly for their shares. I am sure they don't only want to get the money back they lend Mymetics. They want as much as possible, and if they can reach that goal we will participate.
I very well know that things currently don't look good. But to be frank we know almost nothing. But we know that if Mymetics has something valuable the involved people don't have to give up - I am pretty sure they have enough money to just continue business and development. Since they dismissed staff they probably exclude that in the current way.
Until now nothing is decided. Perhaps the HIV vaccine is very promising and further steps have to be made which the company in it's current form can't perform.
We know the company nor parts of it or it's intellectual property has benn sold yet. But we don't know that noone is interested. Perhaps some company offered only 2 Billion but management and board means 5 Billion is the minimum.
Or the company is simply worth nothing.
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM